Suramin analogs inhibit human angiogenesis in vitro

Journal of Surgical Research

Volumn 91, Issue 2, 2000, Pages 130-134

  Meyers, Michael O ^a   Gagliardi, Antonio R ^b   Flattmann, Geoffrey J ^a   Su, Joseph L ^a   Wang, Yi Zarn ^a   Woltering, Eugene A ^a,c  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Chemotherapy; Suramin; Suramin analogs

Indexed keywords

NF 145; NF 248; NF 293; SURAMIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PLACENTA; PRIORITY JOURNAL; SWINE; TISSUE CULTURE;

EID: 0034659543     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.2000.5920     Document Type: Conference Paper

References (30)

1. Diaz-Flores L., Gutierrez R., Varela H. Angiogenesis: An update. Histol. Histopathol. 9:1994;807.
2. Klagsbrun, M.Introduction. In D. B. Rifkin and M. Klagsbrun (Eds.), Angiogenesis. Mechanisms and Pathobiology. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1987. Pp. 1-8.
3. Folkman J., Long D. M., Becker F. F. Growth and metastasis of tumor in organ culture. Cancer. 16:1963;453.
4. Folkman J., Cole P., Zimmerman S. Tumor behavior in isolated perfused organs: In vitro growth and metastasis of biopsy material in rabbit and canine intestinal segment. Ann. Surg. 164:1966;491.
5. Folkman J., Merler E., Abernathy C., Williams G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med. 133:1971;275.
6. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990.
7. Norrby K. Angiogenesis: New aspects relating to its initiation and control. APMIS. 105:1997;417.
8. Hawking F. Suramin with special reference to onchocerciasis. Adv. Pharmocol. Chemother. 15:1989;289.
9. La Rocca R., Stein C., Myers C. Suramin: Prototype of a new generation of antitumour compounds. Cancer Cells. 2:1990;106.
10. La Rocca R., Stein C., Danesi R., Jamis-Dow C., Weiss G., Myers C. Suramin in adrenal cancer: Modulation of steroid hormone production, cytotoxicity in vitro and clinical antitumour effect. J. Clin. Endocrinol. Metab. 71:1990;497.
11. Myers C., Cooper M., Stein C., La Rocca R., Walther M., Weiss G., Choyke P., Dawson N., Steinberg S., Uhrich M., Cassidy J., Kohler D., Trepel J., Linehan D. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 10:1992;881.
12. La Rocca R., Myers C., Stein C., Cooper M., Uhrich M. Effect of suramin in patients with refractory nodular lymphomas requiring systemic therapy. Proc. Am. Soc. Clin. Oncol. 9:1990;268.
13. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J. Cell. Biochem. 29:1985;265.
14. Coffey R., Leof E., Shipley G., Moses H. Suramin inhibition of growth factor receptor binding and mitogenicity in ARK-2B cells. J. Cell Physiol. 132:1987;143.
15. Olander J., Connolly D., DeLarco J. Specific binding of vascular permeability factor to endothelial cells. Biochem. Biophys. Res. Commun. 175:1991;68.
16. Stein C., La Rocca R., Thomas R., McAtee N., Myers C. Suramin: An anticancer drug with a unique mechanism of action. J. Clin. Oncol. 7:1989;499.
17. Bojanowski, K, Lelievre, S, Markovits, J, Couprie, J, Jacquemin-Sablon, A, and, Larsen, A. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells, Proc. Natl. Acad. Sci. USA, 89, 3025, 992.
18. Barret J., Ernould A., Rouillon M., Ferry G., Genton A., Boutin J. Studies of the potency of protein kinase inhibitors on ATPase activities. Chem.-Biol. Interact. 86:1993;17.
19. Gagliardi A., Hadd H., Collins D. Inhibition of angiogenesis by suramin. Cancer Res. 52:1992;5073.
20. Pesenti E., Sol F., Mongelli N., Grandi M., Spreafico F. Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity. Br. J. Cancer. 66:1992;367.
21. LaRocca R. V., Meer J., Gilliatt R. W., Stein C. A., Cassidy J., Myers C. E., Dalakas M. C. Suramin-induced polyneuropathy. Neurology. 40:1990;954.
22. Bitton R., Figg W., Venzon D. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J. Clin. Oncol. 13:1995;2223.
23. La Rocca R., Meer J., Gilliatt R. Suramin-induced polyneuropathy. Neurology. 40:1990;954.
24. Firsching A., Nickel P., Mora P., Allolio B. Antiproliferative and angiostatic activity of suramin analogs. Cancer Res. 55:1995;4957.
25. Braddock P., Hu D., Fan T., Stratford I., Harris A., Bicknell R. A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Br. J. Cancer. 69:1994;890.
26. Watson J. C., Gebhardt B. M., Alperin-Lea R. C., Redmann J. G., Woltering E. A. Initiation of kdr gene transcription is associated with conversion of human vascular endothelium to an angiogenic phenotype. Surg. Forum. 47:1996;462.
27. Brown K. J., Maynes S. F., Bezos A., Maguire D. J., Ford M. D., Parish C. R. A novel in vitro assay for human angiogenesis. Lab. Invest. 75:1996;539.
28. Watson J. C., Redmann J. G., Meyers M. O., Alperin-Lea R. C., Gebhardt B. M., Delcarpio J. B., Woltering E. A. Breast cancer increases initiation of angiogenesis without accelerating neovessel growth rate. Surgery. 122:1997;508.
29. Carmichael J., Degraff W. G., Gazdar A. F., Minna J. D., Mitchell J. B. Evaluation of tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res. 47:1987;936.
30. Gagliardi A. R., Kassack M., Kreimeyer A., Muller G., Nickel P., Collins D. C. Antiangiogenic and antioproliferative activity of suramin analogues. Cancer Chemother. Pharmacol. 41:1998;117.